Akero Therapeutics (AKRO) PT Raised to $61 at Cantor Fitzgerald, 'we would be buyers'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Akero Therapeutics (AKRO) PT Raised to $61 at Cantor Fitzgerald, 'we would be buyers'

Akero Therapeutics (AKRO) PT Raised to $50 at Evercore ISI

March 4, 2024 12:13 PM EST

Evercore ISI analyst Josh Schimmer raised the price target on Akero Therapeutics (NASDAQ: AKRO) to $50.00 (from $36.00) while maintaining a Outperform rating.... More

Akero Therapeutics (AKRO) PT Raised to $43 at H.C. Wainwright

March 4, 2024 6:44 AM EST

H.C. Wainwright analyst Ed Arce raised the price target on Akero Therapeutics (NASDAQ: AKRO) to $43.00 (from $40.00) while maintaining a Buy rating.... More

Akero Therapeutics (AKRO) Posts Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

March 4, 2024 6:02 AM EST

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today released preliminary topline week 96 results from HARMONY, a Phase 2b study evaluating the efficacy and safety of its lead product... More